Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Quantum BioPharma (NASDAQ: QNTM) receives FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug designed to rebuild the myelin sheath rather than suppress the immune system — a potential breakthrough in MS treatment. #MultipleSclerosis #Biopharma
2026-09-11T17:03:14.459Z